ICD-10-CM 2027 diagnosis code
T80.82XDComplication of immune effector cellular therapy, subsequent encounter
T80.82XD is a valid, billable ICD-10-CM code for complication of immune effector cellular therapy, subsequent encounter. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.Short description: Complication of immune effector cellular therapy, subs
Code last changed in FY2022 (effective October 1, 2021). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About T80.82XD
T80.82XD is the ICD-10-CM diagnosis code for complication of immune effector cellular therapy, subsequent encounter. It belongs to category T80 (complications following infusion, transfusion and therapeutic injection), block T80-T88 (complications of surgical and medical care, not elsewhere classified) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
The 7th character "D" means subsequent encounter: use it for encounters after active treatment, while the patient is healing or recovering.
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 949 (Aftercare with CC/MCC, relative weight 1.123) and DRG 950 (Aftercare without CC/MCC, relative weight 0.7664), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.
It was added in FY2022, effective October 1, 2021.
7th character
Dsubsequent encounter
Other encounter types for T80.82:
Notes that apply from higher levels
Instructions written at a parent level also apply to T80.82XD.
› From T80.82 Complication of immune effector cellular therapy
› From T80 Complications following infusion, transfusion and therapeutic injection
- complications following perfusion
- bone marrow transplant rejection (T86.01)
- febrile nonhemolytic transfusion reaction (R50.84)
- fluid overload due to transfusion (E87.71)
- posttransfusion purpura (D69.51)
- transfusion associated circulatory overload (TACO) (E87.71)
- transfusion (red blood cell) associated hemochromatosis (E83.111)
- transfusion related acute lung injury (TRALI) (J95.84)
Broader instructions also apply from T80-T88 Complications of surgical and medical care, not elsewhere classified and Chapter 19: Injury, poisoning and certain other consequences of external causes.
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 23 · Factors Influencing Health Status and Other Contacts with Health Services
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2022 (effective 10/1/2021): Added
- No changes since FY2022.
Common questions about T80.82XD
Is T80.82XD billable?
- Yes. T80.82XD is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
What does the "D" at the end of T80.82XD mean?
- It is the 7th character for subsequent encounter. Per the official guidelines, use it for encounters after active treatment, while the patient is healing or recovering.
Can T80.82XD be used as a principal diagnosis?
- Yes. The Medicare Code Editor doesn't restrict T80.82XD as a principal diagnosis.
Is T80.82XD a CC or MCC?
- No. T80.82XD is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does T80.82XD group to?
- T80.82XD is used in the MS-DRG v44.0 logic for MS-DRG 949 (Aftercare with CC/MCC) and MS-DRG 950 (Aftercare without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.